Skip to main content
OpenTrials

Clinical trial condition

Carcinoma, Non-Small-Cell Lung

Explore clinical trials studying Carcinoma, Non-Small-Cell Lung. Study availability and eligibility vary by location and protocol.

4,704 public trials 1,045 recruiting studies
Refine in advanced search Browse all conditions

Carcinoma, Non-Small-Cell Lung trial results

Completed

Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients

NCT03081689

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • Complejo hospitalario de la coruña A Coruña, Coruña, Spain
  • Hospital Reina Sofía Córdoba, Spain
  • Hospital Insular de Gran Canaria Las Palmas de Gran Canaria, Gran Canaria, Spain
  • Hospital Puerta de Hierro Majadahonda, Madrid, Spain
View all 24 locations
View Trial Details
Completed

A Multicountry, Multicentre, Non-interventional, Retrospective Study to Determine Real-world Treatment Patterns and Associated Outcomes After First Line Osimertinib in Patients With Advanced and Metastatic NSCLC EGFRm in the GCC Region

NCT06039683

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +7 more
Locations
  • Research Site Kuwait City, Kuwait
  • Research Site Doha, Qatar
  • Research Site Dammam, Saudi Arabia
  • Research Site Jeddah, Saudi Arabia
View Trial Details
Completed

Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

NCT02892123

Conditions
Adnexal Diseases, Breast Diseases, Breast Neoplasms, +31 more
Locations
  • University of Alabama Birmingham, Alabama, United States
  • USC/Norris Cancer Center Los Angeles, California, United States
  • Hoag Family Cancer Institute Newport Beach, California, United States
  • University of Colorado Cancer Center Aurora, Colorado, United States
View all 17 locations
View Trial Details
Completed

Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)

NCT03515837

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • Cedars-Sinai Medical Center ( Site 0070) Los Angeles, California, United States
  • Pacific Cancer Care ( Site 0058) Monterey, California, United States
  • UC Irvine Medical Center/Chao Family Comprehensive Cancer Center ( Site 0092) Orange, California, United States
  • St. Joseph Heritage Healthcare ( Site 0003) Santa Rosa, California, United States
View all 158 locations
View Trial Details
Completed

Supportive Care Mobile Application for Patients With NSCLC

NCT04629300

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +10 more
Locations
  • Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Mass General/North Shore Cancer Center Danvers, Massachusetts, United States
  • Dana-Farber Brigham Cancer Center at Milford Regional Medical Center Milford, Massachusetts, United States
View Trial Details
Completed

A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)

NCT00739453

Conditions
Advanced Solid Tumors, Bronchial Neoplasms, Carcinoma, Bronchogenic, +29 more
Locations
  • University of Colorado Health Science Center Aurora, Colorado, United States
  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland, United States
  • Hudson-Webber Cancer Research Center, Karmanos Cancer Institute Detroit, Michigan, United States
  • University of Oxford Department of Medical Oncology Oxford, United Kingdom
View Trial Details
Completed

Study of Continuous OSI-906 Dosing

NCT00514007

Conditions
Adnexal Diseases, Advanced Solid Tumors, Breast Diseases, +43 more
Locations
  • Vanderbilt Universtiy Medical Center Nashville, Tennessee, United States
  • The Beatson West of Scotland Cancer Centre Glasgow, United Kingdom
View Trial Details
Completed

Study of Intermittent OSI-906 Dosing

NCT00514306

Conditions
Adnexal Diseases, Advanced Solid Tumors, Breast Diseases, +43 more
Locations
  • MD Anderson Cancer Center Houston, Texas, United States
  • Drug Development Unit, Royal Marsden Hospital Sutton, Surrey, United Kingdom
View Trial Details

Related conditions